Kevin Chang
파트너,
Head of our Greater China Healthcare & Life Sciences practice.
Kevin
Kevin Chang is the head of our Greater China Healthcare & Life Sciences practice and a member of our Private Equity practice.
Kevin regularly advises clients on organization, strategy and transformation, as well as both commercial and launch excellence. His recent client engagements have involved due diligence and sector screening and review efforts for private equity clients, as well as adjacency and business unit strategy across pharmaceuticals and biotechnology.
While with the firm, Kevin has led a commercial excellence exercise for one of the world's leading IVD manufacturers, which doubled the company’s business in China in 5 years.
He is also deeply involved with our local pro bono efforts.
Kevin holds a B.A. in Economics from Cornell University.
Recent Insights
- “Why ESG Matters for Medtech in the Asia-Pacific Region,” Report, 2023년10월25일
- “Healthcare and Life Sciences M&A,” M&A Report, 2023년1월31일, Report
- “Healthcare Private Equity in Asia-Pacific: A Multiyear Growth Trajectory ,” Report, 2022년3월15일
- “Medtech: The Pandemic Has Expanded Needs and Opportunities ,” Report, 2022년3월15일
- “Healthcare IT: Faster, Smarter, Tuned to Value ,” Report, 2022년3월15일